Research Paper Volume 15, Issue 12 pp 5650—5661

Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma


Figure 8. Validation of the immune prognostic model (IPM) in clinical tissue samples by performing qRT-PCR assay in lung adenocarcinoma (LUAD) mucin 16 (MUC16) mutation tissue samples and LUAD non-MUC16 mutation tissue samples.